Enterprise Value
2.038B
Cash
342.3M
Avg Qtr Burn
N/A
Short % of Float
11.55%
Insider Ownership
14.59%
Institutional Own.
73.43%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Cancer, Melanoma | Approved Quarterly sales | |
IMC-F106C (PRAME) Details Cancer, Melanoma | Phase 3 Initiation | |
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Cancer, Melanoma | Phase 3 Initiation | |
KIMMTRAK (Tebentafusp) +/- anti-PD1 Details Cancer, Melanoma | Phase 2/3 Data readout | |
IMC-F106C (PRAME-A02) Details Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer | Phase 1/2 Data readout | |
IMC-I109V Details Viral infection, Hepatocellular carcinoma, Hepatitis B | Phase 1 Data readout | |
IMC-C103C (MAGE-A4) Details Ovarian cancer, Solid tumor/s, Head and neck cancer, Non-small cell lung carcinoma, Cancer, Gastric cancer | Phase 1 Data readout | |
IMC-M113V Details Viral infection, Human immunodeficiency virus | Phase 1 Data readout |